RxDoctor Payments Data

Joyce Loeffler, MD

Urology · Woodland, CANPI 1144253352

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,587 of the $2,609 with a category attached, or 60.9%. 11 manufacturers reported payments, led by Neotract Inc. at 36.0% of the total. Reporting peaked in 2022 at $1,076 and has fallen 98.4% since, to $17 in 2024. That places this record below the midpoint for urology clinicians in CA, where the typical reported total is $2,485.

$2,609in general payments, 2019–2025

Across 24 payments — averaging $108.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$940
  • Boston Scientific$876
  • Cook Medical LLC$161
  • Sanofi$119
  • Olympus America Inc.$119
  • Pfizer$104
  • plus $289 from 5 others

What the payments were for

  • Travel & lodging$1,58761%
  • Food & beverage$1,02139%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,609 in reported general payments places this provider in the 50th percentile of 1,324 urology providers in California.

See all urology providers in California →

Medicare billing

Part B allowed, 2024
$123,645
Medicare patients
237
Services billed
1,394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron65$43,448
Potassium Citrate ErPotassium Citrate36$5,274
Tamsulosin Hcl154$3,100
Finasteride152$2,250
Estradiol19$1,330
Trospium Chloride32$1,175
Methenamine Hippurate30$810
Tadalafil22$753
Doxazosin Mesylate31$640
Oxybutynin Chloride ErOxybutynin Chloride22$631
Alfuzosin Hcl ErAlfuzosin Hcl22$564
Terazosin Hcl14$543
Testosterone Cypionate23$511
Trimethoprim13$385
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim63$232

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$93$43,44865 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,324 urology providers in California.

Other urology in Woodland

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →